OptiLink HF Study: Optimization of Heart Failure Management Using Medtronic OptiVol Fluid Status Monitoring and Medtronic CareLink Network - Full Text View

Sponsors and Collaborators:	Medtronic Bakken Research Center Medtronic IKFE Institute for Clinical Research and Development
Information provided by:	Medtronic Bakken Research Center
ClinicalTrials.gov Identifier:	NCT00769457

Purpose

Patients suffering from heart failure and a marketdly reduced pumping capacity and sometimes de-synchronization of the lower chambers of the heart have a higher risk of suffering sudden cardiac death.

These patients can be treated with an Implantable Cardiac Defibrillator that terminates dangerously fast heartbeats and in case of asynchronous pumping of the heart can also re-synchronize the lower chambers of the heart (ICD- or CRT-D-system). Patients that moreover suffered from a worsening of their cardiac status (cardiac decompensation) and had to be hospitalized for this reason have a higher risc to have following decompensations. New technology, incorporated into modern Medtronic ICD- and CRTD-Systems, that measures the amout of water in the lungs is able to warn before such a dangerous worsening occurs. If coupled with modern data transmitting technology (CareLink), automatic information in case of a worsening of the cardiac status can be sent to caregivers, who in turn can react timely in order to prevent a worsening an subsequent hospitalization.

The study examines to which extent this new technology prevents potentially adverse cardiac situations and / or hospitalizations and has an invluence of the duration of patient´s lives.

Condition	Intervention	Phase
Heart Failure	Device: Access Arm	Phase IV

MedlinePlus related topics: Heart Failure

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Prevention, Randomized, Open Label, Uncontrolled, Parallel Assignment, Efficacy Study
Official Title:	OptiLink HF Study (Optimization of Heart Failure Management Using Medtronic OptiVol® Fluid Status Monitoring and Medtronic CareLink® Network)

Further study details as provided by Medtronic Bakken Research Center:

Primary Outcome Measures:

All-cause of death or unplanned admission to hospital for cardiovascular reason from day 35 after implantation [ Time Frame: 18 Months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Number of HF-related hospitalization during follow-up, HF-related hospitalization, Sum of follow-up days minus days alive and out of the hospital, All cause mortality, Cardiovascular Mortality, [ Time Frame: 18 Months ] [ Designated as safety issue: No ]

Estimated Enrollment:	1000
Study Start Date:	September 2008
Estimated Study Completion Date:	October 2012
Estimated Primary Completion Date:	September 2010 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
1: Experimental Arm with activated OptiVol / Carelink-system, event-triggered physician alert and physician access to Cardiac Compass data	Device: Access Arm Active OptiVol-System with Care-Alert via CareLink
2: No Intervention Arm with standard ICD - CRT-D therapy, no OptiVol and no Carelink

Detailed Description:

The objective of the study is to establish whether the use of event-triggered HF-disease management through Medtronic's OptiVol® fluid status monitoring with an automatically generated wireless CareAlert® notification of the clinician via the Medtronic CareLink® Network can reduce cardiovascular related hospitalizations and the number of deaths in a subject population with HF and ICD / CRT-D treatment as compared to standard clinical assessment. As a measure for the reduction of hospitalizations and deaths the rate of allcause deaths or cardiovascular related hospitalizations will be determined.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria

Subjects have a Medtronic Virtuoso™ ICD single- or dual-chamber or Concerto™ CRT-D or subsequently market released Medtronic device providing at least the same functionality) implanted, including device replacement. Subjects with CRT-D must fulfill CRT-indication as described in the ESC guidelines for cardiac pacing and cardiac resynchronization therapy 2007: EF ≤ 35% and NYHA III, and LVEDD> 55 mm, and QRS ≥ 120 ms, and optimized therapy

Subjects with stable chronic heart failure (CHF) in New York Heart Association (NYHA) class II or III for at least 30 days and left ventricular ejection fraction of no more than 35% (most recent measurement within 6 months prior to randomization by echocardiography or contrast ventriculography, magnetic resonance or nuclear imaging, based on local practice), on optimal target or maximal tolerated dose of ACE-inhibitors or angiotensin receptor blockers, ßblockers and diuretics if clinically indicated to reduce fluid retention and one of the following criteria: At least one hospitalization due to the heart failure within the last 12 months before enrollment or one course of ambulatory IV-or oral diuretic treatment or a BNP value of > 400 pg/ml or a NT-proBNP values > 450 in subject < 50 years, > 900 (50-75 years) and > 1800 subject of than 75 years old within 30 days of enrolment
Written informed consent by the subject for study participation prior to clinical investigation plan specific procedures,
The subject must be able and willing to comply with the clinical investigation plan and willing to remain available for follow-up visits to the study closure,
Subjects or the subject's caregiver must be willing and able to use the Medtronic CareLink® monitor as instructed and to perform the required duties, if subject is randomized to the access arm.

Exclusion Criteria:

Subjects with chronic renal failure needing renal dialysis
Subjects with serum creatinine > 2.5 mg/dl, measured within 14 days prior to enrollment,
Subjects with severe to very severe Chronic Obstructive Pulmonary Disease (COPD) as determined by physician and documented in medical records (Stage III and Stage IV),
Subjects with suspected or confirmed COPD require a current test of lung function (not more than 12 months before inclusion). If the "forced expiratory volume" is <1.0 L/sec,the subject may not participate in the study,
Subjects on the heart transplantation list or subjects with transplanted hearts,
Subjects listed for valve replacement or interventional valve therapy,
Subjects with myocardial infarction within the last 40 days before implant. MI is defined by typical changes in biochemical markers including troponin levels > 3 times the upper limits of normal and creatinine kinase < 2 times of upper limit, or with CKMB greater than the upper limit of normal, combined (for all enzymes) with at least one of the following ischemic symptoms, ECG changes consistent ofdiagnostic ST-T wave changes or pathologic Q waves or new LBBB,
Subjects with stroke within 40 days prior randomization,
Subjects who have had a percutaneous coronary intervention within 3 months prior to randomization,
Subjects with cardiac surgery within 90 days of randomization,
Subjects with complex and uncorrected Congenital Heart Disease,
Subject's life expectancy is less than 18 months in the opinion of the physician,
Subjects in situations that would limit participation, not eligible to receive a CareLink® monitor (e.g. hearing or speech impaired with no family member or caregiver available to assist, or those who spend extended periods abroad, or those who intend to enroll in a study that would preclude use of the monitor),
Subject is participating in a concurrent intervention study,
Subject or the subject's caregiver is unwilling to give consent for the release of information for the evaluation or to give additional consent for the release of subject medical and privacy data for CareLink® subjects,
Subjects with exclusion criteria required by local law (age < 18, women who are pregnant or breastfeeding)

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00769457

Contacts

Contact: Helmut Drexler, MD	0049 051153260 ext 840	drexler.helmut@mh-hannover.de
Contact: Gunnar Klein, MD	0049 051153260 ext 523	klein.gunnar@mh-hannover.de

Locations

Germany, Niedersachsen
Medizinische Hochschule Hannover	Recruiting
Hannover, Niedersachsen, Germany, 30625
Contact: Helmut Drexler, MD 0049511532360 ext 840 drexler.helmut@mh-hannover.de
Contact: Gunnar Klein, MD 00495115326523 klein.gunnar@mh-hannover.de

Sponsors and Collaborators

Medtronic Bakken Research Center

Medtronic

IKFE Institute for Clinical Research and Development

Investigators

Principal Investigator:	Helmut Drexler, MD	Hannover Medical School
Study Chair:	Johannes Brachmann, MD	Klinikum Coburg gGmbH

More Information

Klinik für Kardiologie und Angiologie MHH This link exits the ClinicalTrials.gov site

Responsible Party:	Medizinische Hochschule Hannover ( Professor Dr. med. Helmut Drexler )
Study ID Numbers:	CEN_G_CA_8
Study First Received:	October 8, 2008
Last Updated:	October 8, 2008
ClinicalTrials.gov Identifier:	NCT00769457
Health Authority:	Germany: Federal Institute for Drugs and Medical Devices

Study placed in the following topic categories:

Heart Failure
Heart Diseases

Additional relevant MeSH terms:

Cardiovascular Diseases

ClinicalTrials.gov processed this record on January 15, 2009